Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | IKBKB | O14920 | 1/20 | 0.32 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.31 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL928875 | 0.75 | ALDH1A1 (0.36) | ALDH1A1POLBMAPTSMN1; SMN2IKBKB | |
| SCHEMBL5630218 | 0.74 | NOS3 (0.33) | — | |
| SCHEMBL6840494 | 0.71 | RAB9A (0.43) | ALDH1A1POLBMAPTSMN1; SMN2IKBKB | |
| SCHEMBL21400321 | 0.69 | CYP1A2 (0.53) | SMN1; SMN2 | |
| SCHEMBL16132153 | 0.68 | RAB9A (0.40) | ALDH1A1POLBMAPTSMN1; SMN2MCHR1 | |
| SCHEMBL930107 | 0.67 | S1PR4 (0.35) | ALDH1A1POLBMAPTSMN1; SMN2 | |
| SCHEMBL17804227 | 0.67 | ALDH1A1 (0.45) | ALDH1A1POLBMAPTSMN1; SMN2IKBKB | |
| SCHEMBL27396828 | 0.66 | SMN1; SMN2 (0.59) | ALDH1A1POLBMAPTSMN1; SMN2 | |
| SCHEMBL929424 | 0.65 | KDM4E (0.43) | ALDH1A1POLB | |
| SCHEMBL12303149 | 0.64 | ALDH1A1 (0.51) | ALDH1A1POLBMAPTSMN1; SMN2GRIA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7875600-B2 | Pyrimidine compounds as purine receptor antagonist | VERNALIS (R&D) LIMITED (GB) | 2011-01-25 | — | — | US | disclosed |
| US-20070281936-A1 | To reducte the purinergic neurotransmission; Parkinson's disease; dyskinesias; Movement disorders; Adenosine receptors antagonists; 2-Methylamino-6-(5-methyl-2-furyl)-N-(2-pyridylmethyl)pyrimidine-4-carboxamide | VERNALIS (R & D ) LIMITED (GB) | 2007-12-06 | — | — | US | disclosed |
| EP-1720553-A1 | PYRIMIDINE COMPOUNDS AS PURINE RECEPTOR ANTAGONIST | VERNALIS (R&D) LTD (GB) | 2006-11-15 | — | — | EP | disclosed |
| WO-2005079801-A1 | PYRIMIDINE COMPOUNDS AS PURINE RECEPTOR ANTAGONIST | VERNALIS (R & D) LTD (GB) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070281936-A1 | To reducte the purinergic neurotransmission; Parkinson's disease; dyskinesias; Movement disorders; Adenosine receptors antagonists; 2-Methylamino-6-(5-methyl-2-furyl)-N-(2-pyridylmethyl)pyrimidine-4-carboxamide | ADORA2A, ADORA3, ADORA1 | ALDH1A1 562/4885POLB 2730/4885MAPT 3556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.